Ann Lab Med.  2018 Sep;38(5):481-483. 10.3343/alm.2018.38.5.481.

The 2016 WHO versus 2008 WHO Criteria for the Diagnosis of Chronic Myelomonocytic Leukemia

• Moon Y
• Kim MH
• Kim HR
• Ahn JY
• Huh J
• Huh JY
• Han JH
• Park JS
• Cho SR

• KMID: 2434739
• DOI: http://doi.org/10.3343/alm.2018.38.5.481

Abstract

The 2016 WHO diagnostic criteria for chronic myelomonocytic leukemia (CMML) require both absolute and relative monocytosis (≥1×10⁹/L and ≥10% of white blood cell counts) in peripheral blood. Moreover, myeloproliferative neoplasm (MPN) features in bone marrow and/or MPN-associated mutations tend to support MPN with monocytosis rather than CMML. We assessed the impact of the 2016 WHO criteria on CMML diagnosis, compared with the 2008 WHO criteria, through a retrospective review of the medical records of 38 CMML patients diagnosed according to the 2008 WHO classification. Application of the 2016 WHO criteria resulted in the exclusion of three (8%) patients who did not fulfill the relative monocytosis criterion and eight (21%) patients with an MPN-associated mutation. These 11 patients formed the 2016 WHO others group; the remaining 27 formed the 2016 WHO CMML group. The significant difference in the platelet count and monocyte percentage between the two groups indicated that the 2016 WHO criteria lead to a more homogenous and improved definition of CMML compared with the 2008 WHO criteria, which may have led to over-diagnosis of CMML. More widespread use of molecular tests and more sophisticated clinical and morphological evaluations are necessary to diagnose CMML accurately.

Keyword

Chronic myelomonocytic leukemia; WHO classification; Monocytosis

MeSH Terms

Bone Marrow
Classification
Diagnosis*
Humans
Leukemia, Myelomonocytic, Chronic*
Leukocytes
Medical Records
Monocytes
Platelet Count
Retrospective Studies

Reference

1. Itzykson R, Duchmann M, Lucas N, Solary E. CMML: clinical and molecular aspects. Int J Hematol. 2017; 105:711–719. PMID: 28455647.

2. Santini V, Allione B, Zini G, Gioia D, Lunghi M, Poloni A, et al. A phase II, multicenter trial of decitabine in higher-risk chronic myelomonocytic leukemia. Leukemia. 2018; 32:413–418. PMID: 28607470.

3. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127:2391–2405. PMID: 27069254.

4. Orazi A, Bennett JM, et al. Chronic myelomonocytic leukemia. In : Swerdlow SH, Campo E, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer;2017. p. 82–86.

5. Orazi A, Bennett JM, et al. Chronic myelomonocytic leukemia. In : Swerdlow SH, Campo E, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer;2008. p. 76–79.

6. Schuler E, Schroeder M, Neukirchen J, Strupp C, Xicoy B, Kündgen A, et al. Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias. Leuk Res. 2014; 38:1413–1419. PMID: 25444076.

7. Patnaik MM, Tefferi A. Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia. Blood Cancer J. 2016; 6:e393. PMID: 26849014.

8. Elena C, Gallì A, Such E, Meggendorfer M, Germing U, Rizzo E, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016; 128:1408–1417. PMID: 27385790.

9. Reinig E, Yang F, Traer E, Arora R, Brown S, Rattray R, et al. Targeted next-generation sequencing in myelodysplastic syndrome and chronic myelomonocytic leukemia aids diagnosis in challenging cases and identifies frequent spliceosome mutations in transformed acute myeloid leukemia. Am J Clin Pathol. 2016; 145:497–506. PMID: 27124934.

10. Selimoglu-Buet D, Wagner-Ballon O, Saada V, Bardet V, Itzykson R, Bencheikh L, et al. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. Blood. 2015; 125:3618–3626. PMID: 25852055.